Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience

Blog Article

Background.Treatment options of recurrent malignant gliomas are keychron m4 very limited and with a poor survival benefit.The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial.

Patients and methods.The medical documentation of 19 adult patients with nordic forge rounding hammer recurrent malignant gliomas was retrospectively reviewed.All patients received bevacizumab (10 mg/kg) and irinotecan (340 mg/m2 or 125 mg/m2) every two weeks.

Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated.